blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2552462

EP2552462 - CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.10.2016
Database last updated on 09.09.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Rosalind Franklin University of Medicine and Science
3333 Green Bay Road
North Chicago, IL 60064 / US
[2013/06]
Inventor(s)01 / RISER, Bruce
313 54th Street
Kenosha Wisconsin 53140 / US
 [2013/06]
Representative(s)AWA Sweden AB
Box 5117
200 71 Malmö / SE
[N/P]
Former [2015/51]Jakobsson, Jeanette Helene
Awapatent AB
P.O. Box 5117
200 71 Malmö / SE
Former [2013/06]Jakobsson, Jeanette Helene
Awapatent AB
Matrosgatan 1
P.O. Box 5117
20071 Malmö / SE
Application number, filing date11763563.104.04.2011
[2015/51]
WO2011US31121
Priority number, dateUS20100341694P02.04.2010         Original published format: US 341694 P
[2013/06]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011123858
Date:06.10.2011
Language:EN
[2011/40]
Type: A2 Application without search report 
No.:EP2552462
Date:06.02.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 06.10.2011 takes the place of the publication of the European patent application.
[2013/06]
Type: B1 Patent specification 
No.:EP2552462
Date:16.12.2015
Language:EN
[2015/51]
Search report(s)International search report - published on:US24.11.2011
(Supplementary) European search report - dispatched on:EP14.11.2013
ClassificationIPC:A61K35/12, A61K38/10, C07K7/08, A61P9/10, A61P35/00, A61P19/08, A61P43/00, A61P9/00, A61N1/30
[2013/06]
CPC:
A61K38/10 (EP,US); A61K38/08 (EP,US); A61P1/02 (EP);
A61P1/16 (EP); A61P11/00 (EP); A61P13/12 (EP);
A61P17/00 (EP); A61P17/02 (EP); A61P19/00 (EP);
A61P19/02 (EP); A61P19/08 (EP); A61P25/00 (EP);
A61P27/02 (EP); A61P3/10 (EP); A61P35/00 (EP);
A61P43/00 (EP); A61P9/00 (EP); A61P9/10 (EP);
A61P9/12 (EP); C07K14/4743 (EP,US); C07K14/475 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/06]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:CCN3-PEPTIDE UND ANALOGE DAVON ZUR THERAPEUTISCHEN VERWENDUNG[2013/06]
English:CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE[2013/06]
French:PEPTIDES CCN3 À VISÉE THÉRAPEUTIQUE ET LEURS ANALOGUES[2013/06]
Entry into regional phase05.10.2012National basic fee paid 
05.10.2012Search fee paid 
05.10.2012Designation fee(s) paid 
05.10.2012Examination fee paid 
Examination procedure05.10.2012Examination requested  [2013/06]
28.03.2014Amendment by applicant (claims and/or description)
02.07.2015Communication of intention to grant the patent
22.10.2015Fee for grant paid
22.10.2015Fee for publishing/printing paid
22.10.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.07.2015
Opposition(s)19.09.2016No opposition filed within time limit [2016/47]
Fees paidRenewal fee
29.04.2013Renewal fee patent year 03
25.03.2014Renewal fee patent year 04
10.04.2015Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.04.2011
AL16.12.2015
AT16.12.2015
BG16.12.2015
CY16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
MC16.12.2015
MK16.12.2015
PL16.12.2015
RO16.12.2015
RS16.12.2015
SI16.12.2015
SK16.12.2015
SM16.12.2015
TR16.12.2015
NO16.03.2016
GR17.03.2016
IE04.04.2016
LU04.04.2016
IS16.04.2016
PT18.04.2016
MT30.04.2016
[2018/46]
Former [2018/38]HU04.04.2011
AT16.12.2015
BG16.12.2015
CY16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
MC16.12.2015
MK16.12.2015
PL16.12.2015
RO16.12.2015
RS16.12.2015
SI16.12.2015
SK16.12.2015
SM16.12.2015
TR16.12.2015
NO16.03.2016
GR17.03.2016
IE04.04.2016
LU04.04.2016
IS16.04.2016
PT18.04.2016
MT30.04.2016
Former [2018/31]HU04.04.2011
AT16.12.2015
CY16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
MC16.12.2015
MK16.12.2015
PL16.12.2015
RO16.12.2015
RS16.12.2015
SI16.12.2015
SK16.12.2015
SM16.12.2015
TR16.12.2015
NO16.03.2016
GR17.03.2016
IE04.04.2016
LU04.04.2016
IS16.04.2016
PT18.04.2016
MT30.04.2016
Former [2018/29]HU04.04.2011
AT16.12.2015
CY16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
MC16.12.2015
MK16.12.2015
PL16.12.2015
RO16.12.2015
RS16.12.2015
SI16.12.2015
SK16.12.2015
SM16.12.2015
TR16.12.2015
NO16.03.2016
GR17.03.2016
IE04.04.2016
LU04.04.2016
IS16.04.2016
PT18.04.2016
Former [2018/28]HU04.04.2011
AT16.12.2015
CY16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
MC16.12.2015
MK16.12.2015
PL16.12.2015
RO16.12.2015
RS16.12.2015
SI16.12.2015
SK16.12.2015
SM16.12.2015
NO16.03.2016
GR17.03.2016
IE04.04.2016
LU04.04.2016
IS16.04.2016
PT18.04.2016
Former [2017/38]AT16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
PL16.12.2015
RO16.12.2015
RS16.12.2015
SI16.12.2015
SK16.12.2015
SM16.12.2015
NO16.03.2016
GR17.03.2016
IE04.04.2016
LU04.04.2016
IS16.04.2016
PT18.04.2016
Former [2017/16]AT16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
PL16.12.2015
RO16.12.2015
RS16.12.2015
SI16.12.2015
SK16.12.2015
SM16.12.2015
NO16.03.2016
GR17.03.2016
LU04.04.2016
IS16.04.2016
PT18.04.2016
Former [2017/04]AT16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
PL16.12.2015
RO16.12.2015
RS16.12.2015
SK16.12.2015
SM16.12.2015
NO16.03.2016
GR17.03.2016
LU04.04.2016
IS16.04.2016
PT18.04.2016
Former [2016/49]AT16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
PL16.12.2015
RO16.12.2015
RS16.12.2015
SK16.12.2015
SM16.12.2015
NO16.03.2016
GR17.03.2016
IS16.04.2016
PT18.04.2016
Former [2016/38]AT16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
RO16.12.2015
RS16.12.2015
SK16.12.2015
SM16.12.2015
NO16.03.2016
GR17.03.2016
IS16.04.2016
PT18.04.2016
Former [2016/36]AT16.12.2015
CZ16.12.2015
EE16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
RO16.12.2015
RS16.12.2015
SK16.12.2015
NO16.03.2016
GR17.03.2016
Former [2016/34]CZ16.12.2015
FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
RS16.12.2015
NO16.03.2016
GR17.03.2016
Former [2016/25]FI16.12.2015
HR16.12.2015
LT16.12.2015
LV16.12.2015
RS16.12.2015
NO16.03.2016
GR17.03.2016
Former [2016/24]FI16.12.2015
HR16.12.2015
LT16.12.2015
RS16.12.2015
NO16.03.2016
GR17.03.2016
Former [2016/23]HR16.12.2015
LT16.12.2015
RS16.12.2015
NO16.03.2016
Former [2016/21]LT16.12.2015
NO16.03.2016
Former [2016/20]LT16.12.2015
Documents cited:Search[Y]FR2858234  (CENTRE NAT RECH SCIENT [FR], et al) [Y] 1-12* page 2, line 9 - page 3, line 25 *;
 [Y]WO2008035024  (UNIV BELFAST [GB], et al) [Y] 1-12 * page 4, line 11 - page 5, line 6 * * page 8, line 5 - page 13, line 30 *
International search[Y]WO2006036962  (LAU LESTER F [US]);
 [X]US2006178332  (RISER BRUCE L [US]);
 [Y]US2010004169  (IRVINE ALEXANDRA ELIZABETH [GB], et al);
 [A]  - GUPTA ET AL., "NOV (CCN3) functions as a regulator of human hematopoietic stern or progenitor cells.", SCIENCE, (2007), vol. 316, no. 5824, pages 590 - 593, XP008166533

DOI:   http://dx.doi.org/10.1126/science.1136031
 [A]  - UNIPROT, (20100302), Database accession no. P48745, XP008166529
by applicantUS7780949
    - PERBAL B., "NOV and the CCN family of genes: structural and functional issues", MOLECULAR PATHOLOGY, (2001), vol. 54, doi:doi:10.1136/mp.54.2.57, pages 57 - 79, XP008010743

DOI:   http://dx.doi.org/10.1136/mp.54.2.57
    - BRIGSTOCK D. R., "Regulation of angiogenesis and endothelial cell function by connective tissue growth factor", FEBS LETTERS, (2003), vol. 327, pages 125 - 130
    - MASON, R., "Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?", J. CELL COMMUN. SIGNAL, (2009), vol. 3, pages 95 - 104
    - DEAN R.G.; BALDING L.; CANDIDO R.; BUMS W.C.; CAO Z.; TWIGG S.M.; BURRELL L,M., "Connective tissue growth factor and cardiac fibrosis after myocardial infarction", JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, (2005), vol. 53, no. 10, pages 1245 - 56
    - SHI-WEN X.; PENNINGTON D.; HOLMES A.; LEASK A.; BRADHAM D.; BEAUCHAMP J.R.; FONSECA C.; DU BOIS R.M.; MARTIN G.R.; BLACK C.M., "Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis", EXPERIMENTAL CELL RESEARCH, (2000), vol. 259, no. 1, pages 213 - 24
    - OZAKI S.; SATO Y.; YASOSHIMA M.; HARADA K.; NAKANUMA Y., "Diffuse expression of heparan sulfate proteoglycan and connective tissue growth factor in fibrous septa with many mast cells relate to unresolving hepatic fibrosis of congenital hepatic fibrosis", LIVER INTERNATIONAL., (2005), vol. 25, no. 4, pages 817 - 28
    - SAKAMOTO N.; SUGIMURA K.; KAWASHIMA H.; TSUCHIDA K.; TAKEMOTO Y.; NAGANUMA T.; TATSUMI S.; NAKATANI T., "Influence of glucose and inflammatory cytokines on TGF-betal and CTGF mRNA expressions in human peritoneal mesothelial cells", INTERNATIONAL JOURNAL OFMOLECULAR MEDICINE, (2005), vol. 15, no. 6, pages 907 - 11
    - ZARRINKALAM K.H.; STANLEY J.M.; GRAY J.; OLIVER N.; FAULL R.J., "Connective tissue growth factor and its regulation in the peritoneal cavity of peritoneal dialysis patients", KIDNEY INTERNATIONAL., (2003), vol. 64, no. 1, pages 331 - 8
    - BRADHAM DM ET AL., "Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to SCR-induced immediate early gene product CEF-10", JOURNAL OF CELL BIOLOGY, (1991), vol. 114, pages 1285 - 1294
    - RISER, BL ET AL., "CCN2 (CTGF): as a possible predictor of diabetic nephropathy: Preliminary report", KIDNEV INTERNATIONAL, (2003), vol. 64, doi:doi:10.1046/j.1523-1755.2003.00130.x, pages 451 - 458, XP002324650

DOI:   http://dx.doi.org/10.1046/j.1523-1755.2003.00130.x
    - FK TAM ET AL., "Urinary monocyte chemoattractant protein- (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy", CYTOKINE, (2009), vol. 47 1, doi:doi:10.1016/j.cyto.2009.04.001, pages 37 - 42, XP026211841

DOI:   http://dx.doi.org/10.1016/j.cyto.2009.04.001
    - CANCER RESEARCH, (2000), vol. 60, pages 5602 - 5607
    - TSAI ET AL., "Expression and regulation of Cyr61 in human breast cancer cell lines", ONCOGENE, (2000), vol. 21, pages 964 - 974
    - SAMPATH ET AL., "Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17 beta-estradiol and overexpression in human breast cancer", ENDOCRINOLOGY, (2001), vol. 142, pages 2540 - 2548
    - SAMPATH ET AL., "Aberrant expression of Cyr 61, a member of the CCN family (i.e. CCN1), and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, (2001), vol. 86, pages 1707 - 1715
    - SAMPATH ET AL., "The angiogenic factor Cyr61 is induced by progestin R5020 and is necessary for mammary adenocarcinorma cell growth", ENDOCRINE, (2002), vol. 18, pages 147 - 150
    - XIE ET AL., "Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease", BREAST CANCER, (2001), vol. 276, pages 14187 - 14194, XP002429498
    - XIE ET AL., "Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features", CANCER RESEARCH, (2002), vol. 61, pages 8917 - 8923, XP009071488
    - RAGEH ET AL., "Steroidal regulation of connective tissue growth factor (CCN2; CTGF) synthesis in the mouse uterus.", MOLECULAR PATHOLOGY, (2001), vol. 56, pages 80 - 85
    - CHEON ET AL., "A genomic approach to identify novel progesterone receptor regulated pathways in the uterus during implantation", MOLECULAR ENDOCRINOLOGY, (2002), vol. 16, pages 2853 - 2871
    - WANDJI ET AL., "Messenger ribonucleic acids for MAC25 and connective tissue growth factor (CTGF) are inversely regulated during folliculogenesis and early luteogenesis", KIDNEY INTERNATIONAL, (2000), vol. 60, pages 96 - 105
    - SLEE ET AL., "Differentiation-dependent expression of connective tissue growth factor and lysyl oxidase messenger ribonucleic acids in rat granulose cells", ENDOCRINOLOGY, (2001), vol. 142, pages 1082 - 1089
    - HARLOW; HILLAR, "Connective tissue growth factor in the ovarian paracrine system", MOLECULAR AND CELLULAR ENDOCRINOLOGY, (2002), vol. 187, pages 23 - 27
    - HARLOW ET AL., "FSH and TGF-beta superfamily members regulate granulose cell connective tissue growth factor gene expression in vitro and in vivo", ENDOCRINOLOGY, (2002), vol. 143, pages 3316 - 3325
    - LIU ET AL., "Gonodotrophins inhibit the expression of insulin-like growth binding protein-related protein-2 mRNA in cultured human granulose-luteal cells", MOLECULAR HUMAN REPRODUCTION, (2002), vol. 8, pages 136 - 141
    - PERBAL B., J CLIN. PATHOL: MOL PATHOL., (2001), vol. 54, pages 57 - 79
    - PERBAL B., J CLIN. PATHOL: MOL PATHOL, (2001), vol. 54, pages 57 - 79
    - KYURKCHIEV S. ET AL., "Potential cellular conformations of the CCN3 (NOV) protein", CELLULAR COMMUNICATION AND SIGNALING, (2004), vol. 2, pages 9 - 18
    - LI, C. L. ET AL., "A role for CCN3 (NOV) in calcium signaling", JOURNAL OF CLINICAL PATHOLOGY: MOLECULAR PATHOLOGY, (2002), vol. 55, pages 250 - 261
    - RISER ET AL., "CCN3 is a negative regulator ofCCN2 and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease", AMERICAN J PATHOLOGY, (2009), vol. 174, no. 5
    - MCCALLUM, L ET AL., "CCN3: a key growth regulator in Chronic Myeloid Leukaemia", J CELL COMMUN SIGNAL., (200906), vol. 3, no. 2, pages 115 - 124
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.